Celerion Receives Investment From THL Partners

Celerion is a key partner in helping bring new medicines to market. It provides clinical pharmacology and advanced bioanalytical services, including early human testing, cardiac safety studies, drug interaction testing, and other complex clinical trials needed for regulatory approval and drug labeling.

The company operates an integrated model that combines clinical research units and laboratory services to deliver reliable data for early stage trials. With facilities across North America, and Europe, Celerion supports pharmaceutical and biotech companies through a network of specialized research sites and labs.

Pharma services is a core focus for THL Partners within its healthcare investments, with over 25 years of experience across clinical development, manufacturing and commercialization. Over time the firm has built strong industry knowledge and relationships through working with companies across the ecosystem, supporting its strategy of developing deep expertise, and repeatable value creation in key healthcare subsectors.

“Celerion has built a reputation as a trusted partner to leading pharmaceutical and biotechnology companies, grounded in scientific rigor, operational excellence, and a deep commitment to advancing patient outcomes,” said Dr. Susan Thornton, Ph.D., founder, and Chief Executive Officer of Celerion. “We are proud of what our team has accomplished and excited to partner with THL to build on this strong foundation. THL’s deep experience in pharma services and collaborative approach make them an ideal partner as we continue to invest in our capabilities and support our customers in bringing new therapies to market. This partnership will allow us to invest further in the capabilities, and capacity our customers need as they advance increasingly complex molecules through clinical development.”

Read More:Vertical Bridge Receives $1.5 Billion Strategic Equity Investment

“Celerion plays a critical role in bringing new medicines to market, particularly at the earliest and most complex stages of clinical pharmacology,” said Megan Preiner, Managing Director at THL. “With its differentiated clinical infrastructure, leading scientific expertise, and strong customer relationships, Celerion is one of the few organizations globally to integrate clinical pharmacology and bioanalytical capabilities under one roof—a combination that is increasingly valuable as drug development grows more complex. We are excited to partner with the Celerion team to support its next phase of growth and innovation.”

“THL has been investing in pharma services for more than three decades, building a deep understanding of what drives success across the clinical development value chain,” said Joshua Nelson, Head of THL’s Healthcare team. “We believe that experience—combined with our long-standing focus on the sector—positions us to be a highly effective partner to Susan and her talented team as they continue to scale this compelling platform and support increasingly complex drug development programs.”

About Celerion

Founded in 2010 Celerion is a global leader in early-stage clinical research, helping drug developers make faster, more informed decisions. With over 50 years of combined expertise, it specializes in Phase 1 studies, including first in human trials, drug-drug interaction testing, cardiac safety, bioequivalence, metabolism and pharmacokinetics in patients. It also offers data management, biostatistics, clinical monitoring, and bioanalytical services.

About THL

Founded in 1974 THL Partners is a private equity firm that invests in mid-sized growth companies in healthcare, financial technology, and technology services. It combines industry expertise with operational support to help management teams build strong, long term businesses.

Read More:Point2 Closes Series B Extension Funding